FDA advisers back a $949 blood test for 50 cancers — here is what it finds, what it misses and who pays

On Wednesday, an advisory panel to the Food and Drug Administration did something no federal panel had done before: it endorsed a single blood draw that screens for dozens of cancers at once. The test is Galleri, made by Grail. It is already sold by prescription for $949, out of pocket, and it looks for traces of tumor DNA in your blood.

If you are over 50, you will hear about this test from ads, from wellness apps and maybe from a relative who swears by it. Before you spend a month's grocery budget on it, you should know what the vote actually said. It was more cautious than the headlines.

What the panel actually voted on

The FDA asked its Molecular and Clinical Genetics Devices Panel three questions. Is the test safe? Yes, 10-0. That is the easy one: it is a blood draw. Is there reasonable assurance it is effective? That one split 6-4. Do the benefits outweigh the risks for people 50 and older? 7-2, with one abstention.

Read those together and you get the real message. The experts think the test is worth having on the market. They are much less sure it does what the marketing implies. The panel recommended that Grail's materials tell people to keep getting their routine screenings, and that the company avoid calling Galleri an "early" detection tool.

The FDA does not have to follow its advisers, though it usually does. Grail says a decision is expected in the coming months.

The numbers behind "detects up to 50 cancers"

Here is the part the ads will not lead with. In PATHFINDER 2, a study of 32,007 adults in North America, the test caught 39.3% of all cancers diagnosed within a year of the blood draw. That means roughly six in ten cancers went undetected. For a pre-selected list of 12 cancers that cause about two-thirds of cancer deaths, it did better: 69.8%.

When it does flag something, it is right about 60% of the time. That is its positive predictive value — the odds that "cancer signal detected" really means cancer. So about four in ten positive results send a healthy person into follow-up scans, specialist visits and weeks of worry. Its specificity of 99.6% keeps that group small in absolute terms, but it is not zero, and the follow-up is not free.

The bigger study, NHS-Galleri in England with 142,250 people, did not meet its main goal of reducing stage III and IV cancers combined. Grail points to a later analysis showing fewer stage IV diagnoses over three years. Phil Castle, who directs cancer prevention at the National Cancer Institute, was not persuaded. "Routine approval and broad population rollout would risk harm and waste resources," he told the panel, arguing that a negative result could give people a false sense of security.

Supporters have a fair point too. Oncologist Tom Beer, who works on a rival test at Abbott, told NPR that about 70% of cancer diagnoses and deaths come from cancers with no routine screening at all, such as pancreatic cancer. A test that catches some of those is something that does not exist today.

Who pays — now and later

Right now, you do. Galleri costs $949 with a doctor's prescription, and it is also sold through direct-to-consumer platforms like Function Health. Private insurers generally treat it as unproven, so do not expect your plan to reimburse it without a fight.

That is why the FDA vote matters so much to Grail. Congress has already passed a law letting Medicare cover multi-cancer detection tests once the FDA approves them. Reporting ahead of the meeting said Medicare coverage of Galleri could begin in 2028 if the test clears the agency. Private insurers usually feel pressure to follow Medicare. A $949 cash test could become a routine line on your EOB (explanation of benefits).

Note what the ACA's free-preventive-care rule does not do here. The zero-copay screenings your plan must cover come from the U.S. Preventive Services Task Force's A and B list. Galleri is not on it, and FDA approval does not put it there.

Who this helps — and who should wait

This test is not a replacement for anything. Grail itself says so. If you are 50 and have not had a colonoscopy (or a stool test), a mammogram if it applies to you, or a lung scan if you are a long-time smoker, those come first. They are proven, and under the ACA most plans must cover them at no cost to you.

Where a test like Galleri might add something is for cancers nobody screens for today. Whether that is worth $949 of your money, before the FDA and Medicare decide, is a question for your doctor. Ask about your personal risk, not the ad.

What to actually do

• Get the proven screenings first. See our guide to free preventive screenings for what your plan must cover at $0.
• If you are offered Galleri, ask three questions: Who orders the follow-up if it is positive? What will that follow-up cost under my plan? And does a negative result change any screening I would otherwise get? (It should not.)
• Price the follow-up, not just the test. A positive result can mean CT or PET scans. Our guide to direct-to-consumer tests explains how a cash test can become an insured bill.
• Wait if money is tight. If the FDA approves it and Medicare coverage follows, the price for many people could fall to little or nothing. There is no rush to pay $949 for a test your doctor has not recommended.

The panel did not say Galleri finds cancer early. It said the test is probably worth having around. That is a real step, and a much smaller one than a $949 price tag suggests.